OLEMA PHARMACEUTICALS, INC. Proceeds from Sale and Maturity of Marketable Securities
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Proceeds from Sale and Maturity of Marketable Securities of $163.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $89.30M, a 33.09% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $74.47M, a 23.83% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $91.17M, a 21.87% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $88.92M, a 4.79% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $344.96M, a 14.38% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $301.59M, a 20.27% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $250.76M, a 17.92% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $305.50M, a 43.36% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $89.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $163.77M 10-Q · filed 2026-08-10 | $254.94M derived: sum of 3 quarters · filed 2026-08-10 | $343.86M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $74.47M 10-Q · filed 2026-05-12 | $165.64M derived: sum of 2 quarters · filed 2026-05-12 | $254.56M derived: sum of 3 quarters · filed 2026-05-12 | $321.66M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $91.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $180.09M derived: sum of 2 quarters · filed 2026-03-16 | $247.19M derived: sum of 3 quarters · filed 2026-08-10 | $344.96M 10-K · filed 2026-03-16 |
| 2025-09-30 | $88.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $156.02M derived: sum of 2 quarters · filed 2026-08-10 | $253.79M 10-Q · filed 2025-11-10 | $328.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $67.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $164.87M 10-Q · filed 2026-08-10 | $239.68M derived: sum of 3 quarters · filed 2026-08-10 | $333.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $97.77M 10-Q · filed 2026-05-12 | $172.58M derived: sum of 2 quarters · filed 2026-05-12 | $265.97M derived: sum of 3 quarters · filed 2026-05-12 | $343.26M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $74.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $168.20M derived: sum of 2 quarters · filed 2026-03-16 | $245.49M derived: sum of 3 quarters · filed 2026-03-16 | $301.59M 10-K · filed 2026-03-16 |
| 2024-09-30 | $93.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $170.69M derived: sum of 2 quarters · filed 2025-11-10 | $226.79M 10-Q · filed 2025-11-10 | $280.79M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $77.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $133.39M 10-Q · filed 2025-08-11 | $187.39M derived: sum of 3 quarters · filed 2025-08-11 | $257.89M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $56.10M 10-Q · filed 2025-05-13 | $110.10M derived: sum of 2 quarters · filed 2025-05-13 | $180.60M derived: sum of 3 quarters · filed 2025-05-13 | $245.10M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $54.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $124.50M derived: sum of 2 quarters · filed 2025-03-18 | $189.00M derived: sum of 3 quarters · filed 2025-03-18 | $250.76M 10-K · filed 2025-03-18 |
| 2023-09-30 | $70.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $135.00M derived: sum of 2 quarters · filed 2024-11-12 | $196.76M 10-Q · filed 2024-11-12 | $257.76M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $64.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $126.26M 10-Q · filed 2024-08-06 | $187.26M derived: sum of 3 quarters · filed 2024-08-06 | $226.01M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $61.76M 10-Q · filed 2024-05-08 | $122.76M derived: sum of 2 quarters · filed 2024-05-08 | $161.51M derived: sum of 3 quarters · filed 2024-05-08 | $218.51M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $61.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $99.75M derived: sum of 2 quarters · filed 2024-03-11 | $156.75M derived: sum of 3 quarters · filed 2024-03-11 | $305.50M 10-K · filed 2024-03-11 |
| 2022-09-30 | $38.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $95.75M derived: sum of 2 quarters · filed 2023-11-07 | $244.50M 10-Q · filed 2023-11-07 | $271.15M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $57.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $205.75M 10-Q · filed 2023-08-08 | $232.41M derived: sum of 3 quarters · filed 2023-08-08 | $351.85M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $148.75M 10-Q · filed 2023-05-09 | $175.41M derived: sum of 2 quarters · filed 2023-05-09 | $294.85M derived: sum of 3 quarters · filed 2023-05-09 | $360.85M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $26.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $146.10M derived: sum of 2 quarters · filed 2023-03-09 | $212.10M derived: sum of 3 quarters · filed 2023-03-09 | $213.10M 10-K · filed 2023-03-09 |
| 2021-09-30 | $119.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $185.45M derived: sum of 2 quarters · filed 2022-11-08 | $186.45M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $66.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $67.00M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |